Bausch Health Reports Strong Q2 Results and Raises Full-Year Outlook
Bausch Health Cos Inc (NYSE:BHC) reported strong second-quarter results driven by growth in its Salix, international, and Solta Medical segments. Excluding Bausch + Lomb, revenue rose 16% to $1.458 billion with adjusted EBITDA increasing 28% to $865 million. XIFAXAN contributed significantly to this performance, seeing a 26% increase in revenue due to favorable net pricing and volume optimization post-Medicaid exit. The company raised its full-year outlook for revenue, adjusted EBITDA, and cash flow from operations. However, management warned of potential headwinds in the second half of 2026 including gross-to-net adjustments, Aplenzin's loss of exclusivity, and Medicaid erosion, which could impact earnings by up to $150 million. Bausch Health also continues evaluating strategic options for Bausch + Lomb. Consolidated revenue reached $2.852 billion with adjusted EBITDA at $1.075 billion.
Tickers: $BHC